U.S. markets open in 3 minutes
  • S&P Futures

    3,813.00
    -3.75 (-0.10%)
     
  • Dow Futures

    31,245.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    12,664.00
    -17.75 (-0.14%)
     
  • Russell 2000 Futures

    2,200.30
    -5.50 (-0.25%)
     
  • Crude Oil

    62.34
    +1.06 (+1.73%)
     
  • Gold

    1,711.40
    -4.40 (-0.26%)
     
  • Silver

    26.05
    -0.34 (-1.28%)
     
  • EUR/USD

    1.2039
    -0.0028 (-0.23%)
     
  • 10-Yr Bond

    1.4770
    +0.0070 (+0.48%)
     
  • Vix

    26.27
    +2.17 (+9.00%)
     
  • GBP/USD

    1.3969
    +0.0016 (+0.11%)
     
  • USD/JPY

    107.4460
    +0.4440 (+0.41%)
     
  • BTC-USD

    49,714.01
    -2,082.02 (-4.02%)
     
  • CMC Crypto 200

    997.49
    +10.28 (+1.04%)
     
  • FTSE 100

    6,649.62
    -25.85 (-0.39%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

3 Cheap Stocks for the Short-Term Investor

  • Oops!
    Something went wrong.
    Please try again later.
GuruFocus.com
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

There are some investors who buy stocks that are trading below their liquidation value because they believe that they can make a profit out of their investments after the market has reappraised the share prices up to a value near or above the liquidation value in the short term.

These investors calculate the liquidation value of these so-called "Benjamin Graham net-net working capital" stocks as "cash and short-term investments + 75% of receivables + 50% of inventory - total liabilities."


Here are some results of my research for stocks whose share prices are trading below their net-net working capital.

Benitec Biopharma Inc

The first stock under consideration is Benitec Biopharma Inc (NASDAQ:BNTC), a Hayward, California-based biotech developer of innovative treatments for genetic diseases.

The stock was trading at $7.68 per American Depository Receipt at close on Wednesday, which is largely below the net-net working capital of $12.50 per ADR calculated based on figures from the most recent quarter's balance sheet.

The company holds a GuruFocus financial strength rating of 4 out of 10 and a GuruFocus profitability rating of 3 out of 10.

As a result of a 39.8% fall over the past year, the stock has a market capitalization of $2.47 billion and a 52-week range of $4.14 to $29.55.

Wall Street sell-side analysts recommend a buy rating with an average target price of $14 per ADR for the stock.

Evogene Ltd

The second stock to consider is Evogene Ltd (NASDAQ:EVGN), an Israeli biotech developer of various products for life science markets in Israel and the U.S.

The stock was trading at $1.05 per share at close on Wednesday, which compared to a net-net working capital of $1.27 (based on figures from most recent quarter's balance sheet), yields a discount margin of 17.3%.

The company holds a GuruFocus financial strength rating of 4 out of 10 and a GuruFocus profitability rating of 1 out of 10.

Following a 28% decline over the past year, the stock has a market capitalization of $26.4 million and a 52-week range of $0.75 to $2.46.

Wall Street sell-side analysts have recommended a hold rating with an average target price of $8 per share for the company.

The company's top fund holder is WADDELL & REED FINANCIAL INC with 10.71% of shares outstanding, followed by UBS Group AG with 5.27% and GOLDMAN SACHS GROUP INC with 2.98%.

Qudian Inc

The third stock under consideration is Qudian Inc (NYSE:QD), a Chinese online provider of consumer credit products in the People's Republic of China.

The stock was trading at $1.70 per American Depository Receipt at close on Wednesday, which was approximately 36.3% below the net-net working capital of about $2.67 per ADR (based on figures from the most recent quarter's balance sheet).

The company holds a GuruFocus financial strength rating of 7 out of 10 and a GuruFocus profitability rating of 5 out of 10.

As a result of an 81.4% fall in the past year, the market capitalization now trades at around $431.32 million and the 52-week range is $1.21 to $9.21.

As of July, the stock has three strong buy recommendation ratings, three buy recommendation ratings and one hold recommendation rating on Wall Street. The average target price is $1.59 per share.

The company's top fund holder is ACADIAN ASSET MANAGEMENT LLC with 2.65% of shares outstanding, followed by Greenwoods Asset Management Ltd with 2.16% and APG All Pensions Group NV with 1.85%.

Disclosure: I have no positions in any securities mentioned.

This article first appeared on GuruFocus.